This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GRAY Graybug Vision (GRAY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Graybug Vision Stock (NASDAQ:GRAY) Get Graybug Vision alerts:Sign Up Key Stats Today's Range$0.84▼$1.1450-Day Range$0.59▼$1.0652-Week Range$5.00▼$22.12Volume2.99 million shsAverage Volume2,165 shsMarket Capitalization$1.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. The company’s proprietary Depot Technology Platform is designed to deliver sustained-release formulations of biologically active agents directly to the back of the eye, with the goal of reducing treatment burden and improving patient outcomes. Graybug’s lead product candidate, GB-102, is a long-acting formulation of sunitinib malate being investigated for the treatment of wet age-related macular degeneration (wet AMD). The company is also advancing GB-401, a sustained-release formulation of travoprost for the management of open-angle glaucoma. Graybug Vision’s clinical development program for GB-102 has included Phase I/II studies in patients with wet AMD, demonstrating a favorable safety profile and potential for extended dosing intervals compared to existing standards of care. The company has expanded its clinical footprint into multiple centers across the United States and has established collaborations with ophthalmology specialists to support ongoing and future trials. In parallel, preclinical and early clinical work on GB-401 aims to address unmet needs in glaucoma management by offering sustained intraocular pressure control without the need for daily eye drops. Founded with the mission of transforming ophthalmology through sustained-delivery technologies, Graybug Vision is headquartered in New York City. The company is led by President and Chief Executive Officer David R. Guyer, M.D., who brings over two decades of experience in ophthalmic drug development. Under his leadership, Graybug has assembled a team with deep expertise in pharmacology, formulation science, and clinical trial execution, positioning the company to advance its pipeline and explore additional indications for its Depot Technology Platform.AI Generated. May Contain Errors. Read More Receive GRAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Graybug Vision and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRAY Stock News HeadlinesGrayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG)June 3, 2026 | globenewswire.comGrayscale Investments® Announces Rebalancing of Multi-Asset Funds for First Quarter 2026May 6, 2026 | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits. | Porter & Company (Ad)Grayscale Zcash Trust: A 20% ETF Conversion Arb OpportunityDecember 23, 2025 | seekingalpha.comGrayscale Investments Files For IPO On Declining Results And Parent Legal CloudsNovember 17, 2025 | seekingalpha.comGENAI ANNOUNCES CHANGE OF MANAGEMENT AND APPOINTMENT OF PATRICK GRAY AS CEOJanuary 6, 2025 | prnewswire.comOppenheimer Sticks to Its Buy Rating for CalciMedica (CALC)November 1, 2024 | markets.businessinsider.comAge-Related Macular DegenerationOctober 23, 2024 | benzinga.comSee More Headlines GRAY Stock Analysis - Frequently Asked Questions How were Graybug Vision's earnings last quarter? Graybug Vision, Inc. (NASDAQ:GRAY) announced its earnings results on Thursday, November, 11th. The company reported ($5.32) EPS for the quarter, missing the consensus estimate of ($5.18) by $0.14. When did Graybug Vision's stock split? Shares of Graybug Vision reverse split on Monday, March 20th 2023.The 1-14 reverse split was announced on Monday, March 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Graybug Vision IPO? Graybug Vision (GRAY) raised $75 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 4,700,000 shares at $15.00-$17.00 per share. SVB Leerink and Piper Sandler served as the underwriters for the IPO and Needham & Co. and Wedbush PacGrow were co-managers. What other stocks do shareholders of Graybug Vision own? Based on aggregate information from My MarketBeat watchlists, some other companies that Graybug Vision investors own include Tesla (TSLA), Plug Power (PLUG), NIO (NIO), Moderna (MRNA), Pinterest (PINS). Company Calendar Last Earnings11/11/2021Today8/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GRAY CIK1534133 Webwww.graybug.com PhoneN/AFaxN/AEmployees27Year Founded2011Profitability EPS (Trailing Twelve Months)($24.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.61% Return on Assets-71.34% Debt Debt-to-Equity RatioN/A Current Ratio10.73 Quick Ratio10.72 Sales & Book Value Annual Sales$426.96 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book0.63Miscellaneous Outstanding Shares1,571,000Free Float20,250,000Market Cap$1.67 million OptionableNot Optionable Beta1.20 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:GRAY) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
